SG
MDGL icon

Strid Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Strid Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Hold
2,500
– – 0.15% 32
2026
Q1 		$1.31M Hold
2,500
– – 0.16% 30
2025
Q4 		$1.46M Hold
2,500
– – 0.18% 28
2025
Q3 		$1.15M Hold
2,500
– – 0.15% 31
2025
Q2 		$757K Buy
+2,500
New +$745K 0.11% 41

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Strid Group's MDGL Position: Q2 2026 in Review

Strid Group held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 2,500 shares worth $1.34M. The position accounts for 0.15% of the portfolio, ranked #32.

Strid Group first reported a position in MDGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.46M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Strid Group held 2,500 shares of Madrigal Pharmaceuticals worth $1.34M as of Q2 2026.
  • Strid Group left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.15% of Strid Group's portfolio in Q2 2026, its #32 holding.
  • Strid Group first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Strid Group's Madrigal Pharmaceuticals position peaked at $1.46M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Strid Group's 13F filing for Q2 2026, filed 23 Jul 2026.